Core Viewpoint - Federal Pharmaceutical (03933) announced that its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., received clinical trial approval from the National Medical Products Administration of China for its innovative drug UBT251 injection, targeting moderate to severe obstructive sleep apnea (OSA) associated with obesity [1] Group 1: Product Development - UBT251 injection is a multi-target peptide receptor agonist developed by Federal Biotech, which acts on GLP-1, GIP, and GCG receptors to lower blood sugar and inhibit weight gain [1] - The drug is expected to address significant unmet clinical needs in the OSA treatment field, particularly for weight management [1] - UBT251 injection has also initiated Phase II clinical studies in China for indications including overweight or obesity, type 2 diabetes, metabolic-associated fatty liver disease, and chronic kidney disease [1] Group 2: Market Position and Future Plans - As the first chemically synthesized GLP-1/GIP/GCG tri-target receptor agonist new drug in China, UBT251 positions the company prominently in the research field of such medications [1] - The company aims to continue its focus on new product development to enhance its competitiveness and creativity in the biopharmaceutical industry, which is expected to generate greater returns for the company and its shareholders [1]